| Symbol | SION |
|---|---|
| Name | SIONNA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 21 HICKORY DRIVE,SUITE 500, WALTHAM, Massachusetts, 02451, United States |
| Telephone | 617-819-2020 |
| Fax | — |
| — | |
| Website | https://www.sionnatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002036042 |
| Description | Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the treatment paradigm for cystic fibrosis (CF) patients. The company focuses on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Their goal is to deliver differentiated medicines that can restore CFTR function as close to normal as possible by directly stabilizing CFTRs nucleotide-binding domain 1 (NBD1). Sionna is currently conducting Phase 1 trials for two highly potent NBD1 stabilizers and developing a portfolio of complementary CFTR modulators designed to work synergistically with their NBD1 stabilizers to improve CFTR function, as observed in preclinical models. Additional info from NASDAQ: |
INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
Read moreRobbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
Read moreSionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky
Read moreInvestigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
Read moreSecurities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Read moreSionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Read moreSecurities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Read moreRobbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
Read moreSION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07108153 | Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, … | Phase2 | Cystic Fibrosis (CF) | Active_Not_Recruiting | 2025-11-03 | 2026-07-01 | ClinicalTrials.gov |
| NCT07035990 | Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SIO… | Phase1 | Cystic Fibrosis (CF) | Recruiting | 2025-07-23 | 2026-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo SION-109 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo SION-2222 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo SION-451 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-109 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-2222 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-451 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | DRUG | Phase PHASE2 | Cystic Fibrosis (CF) | RECRUITING | NCT07108153 |
| SION-719 | DRUG | Phase PHASE2 | Cystic Fibrosis (CF) | RECRUITING | NCT07108153 |
| Placebo SION-109 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo SION-2222 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo SION-451 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-109 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-2222 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-451 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |